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and utility, providing an opportunity to evaluate esti-
mates of utility from physical function. METHODS: A
total of 2070 patients with active RA participated in 4
clinical trials (ARMADA, DE011, DE019 and STAR).
The Health Assessment Questionnaire Disability Index
(HAQ) measured physical function for all patients and
the Health Utilities Index Mark-3 (HUI3) measured
utility for 2000 patients at baseline and months 3 and 6.
HAQ scores range from 0 (good physical function) to 3.
HUI3 was regressed on HAQ using both repeated
measure mixed models and cross-sectional models 
controlling for age, sex, disease duration, clinical trial 
and fatigue (measured by the Functional Assessment of
Chronic Illness Therapy-Fatigue (FACIT-F)). The cross-
sectional models used end-of-study data with Last Obser-
vation Carried Forward (LOCF) imputation. These
analyses include the 1990 patients with non-missing
values for these variables. RESULTS: The mixed models
and the cross-sectional models provided almost identical
coefﬁcient estimates. Disease duration and trial were 
not signiﬁcant and were deleted from the model. Age 
(in years) was statistically signiﬁcant but trivial (b =
0.00087). The basic estimated cross-sectional model was:
HUI3 = 0.76–0.28*HAQ + 0.05*FEMALE (p < 0.0001
for each regressor, Adj. R2 = 0.49). However, the rela-
tionship between HUI3 and HAQ appears to be nonlin-
ear: coefﬁcients for HAQ-squared and HAQ-cubed were
signiﬁcant (p = 0.013 and p = 0.003, respectively) when
added to the regression. Adding FACIT-F to the basic
cross-sectional model substantially improved model ﬁt
(Adj. R2 = 0.63). CONCLUSIONS: The basic algorithm
developed in this study is consistent with published pre-
dictions of utility from HAQ (Kobelt et al., Arthritis and
Rheumatism, 1999). However, these algorithms’ predic-
tions are limited and should only be used when direct
utility scores are not available.
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OBJECTIVES: During the last ten years the inﬂuence 
of pharmacoeconomics has increased in decision-making.
Due to budget constraints, decision makers often have to
choose which intervention is given priority, for example,
using league tables. The current practice of discounting
both health and monetary beneﬁts at the same rate places
a higher priority on direct medical interventions, with
health beneﬁts occurring immediately. Due to this, pre-
ventive interventions such as vaccination strategies are
possibly under-appreciated, leading to inconsistencies.
Some researchers have suggested to not discount health
beneﬁts at all. We developed a novel approach combin-
ing the rationales underlying both theories of fully and
not-at-all discounting of health beneﬁts. We illustrate 
our novel approach with the conjugate meningococcal
B/C vaccine for newborns in the Netherlands.
METHODS: Firstly, we discard the relevance of the
Keeler-Cretin paradox for day-to-day practice. Secondly,
we note that by discounting the analyst implicitly corrects
for a number of uncertainties and preferences, which are
among others time preference and force of innovation.
Our novel approach appreciates these factors, but also
elaborates on the uncertainty that is already implicitly
covered in the concept of life-years gained, which is part
of the QALY assessment. RESULTS: Our illustration 
for vaccination with the conjugate meningococcal B/C
vaccine renders estimates per QALY gained of €16,000
(monetary ﬁgures and QALYs discounted at 4%), €7000
(monetary ﬁgures discounted at 4%, QALYs non-
discounted) and approximately €10,000 (monetary
ﬁgures at 4% and QALYs according to the novel
approach). CONCLUSIONS: We have developed a novel
approach for discounting health beneﬁts that may be 
considered a consensus approach between fully and 
not-at-all discounting of health beneﬁts. The method 
can be applied to vaccines. Its application may ensure a
more proper pharmacoeconomic valuing of vaccination 
strategies.
IN5
ECONOMIC EVALUATION OF A LARGE-SCALE
MENINGOCOCCAL C VACCINATION PROGRAM
IN THE NETHERLANDS
Welte R1, Postma MJ2, Bos JM3, van Alphen L4
1University of Ulm, Ulm, Germany; 2Groningen University
Institute for Drug Exploration/University of Groningen
Research Institute of Pharmacy (GUIDE/GRIP), Groningen,
Netherlands; 3Groningen University Institute for Drug
Exploration (GUIDE), Groningen, Netherlands; 4National
Institute of Public Health and the Environment, Bilthoven,
Netherlands
OBJECTIVES: In the Netherlands, the incidence of
meningococcal C infections has strongly increased during
the last years. Should the Netherlands follow the UK 
and start a large-scale meningococcal C vaccination cam-
paign? We calculated the health effects and costs of such
a vaccination program. METHODS: The health effects,
the costs and savings, as well as the cost-effectiveness of
vaccinating all persons aged 14 months to 19 years in the
Netherlands against meningococcal C infection was esti-
mated, from a societal perspective using a decision ana-
lytic model. Data were derived from the Netherlands
Reference Laboratory for Bacterial Meningitis, the Dutch
costing guidelines, PRISMANT Healthcare, and national
and international literature. Direct and indirect costs
